YZYu Zhao

Yu Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Zhao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Hao Liu

    Vascular and Interventional Radiology Department, Nanfang hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Hua Li

    Nephrology Department, Shaoyifu Hospital, Zhejiang Medical University, Hangzhou, China

    1 shared publication
  • Jianfang Luo

    Cardiology Department, Guangdong provincial people's hospital, Guangzhou, China

    1 shared publication
  • Lan Zhang

    Department of Vascular Surgery, RenJi Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    1 shared publication
  • Lihong Zhang

    Nephrology Department, The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China

    1 shared publication
  • Pei Wang

    Blood Purification Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Drug-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Hemodialysis Fistulae

    by Yiping Zhao, Pei Wang, Yuzhu Wang, Lihong Zhang, Yu Zhao, Hua Li, Qiang He, Hao Liu, Jianfang Luo, Xin Jia, et al.

    Background: The aim of this study was to evaluate the efficacy and safety of paclitaxel-coated balloons (AcoArt Orchid) in treating dysfunctional arteriovenous fistulae. Methods: The drug-eluting balloon for arteriovenous (AV) fistula in China trial was a prospective, multicenter, randomized controlled study. Patients who had ≥50% venous stenosis of the AV fistula and symptoms indicating significant hemodynamic changes were included. After successful predilation with a high-pressure balloon (residual stenosis ≤30%), patients were randomized 1:1 to either a paclitaxel-coated balloon or an uncoated control balloon. The primary efficacy outcome was assessed at 6 months, and safety assessment was conducted within 30 days of the procedure. The 12-month results were also analyzed. Results: The study included 244 patients, equally distributed between the two groups. The primary target lesion patency was 91% (106/116) for the drug-coated balloon (DCB) group and 67% (79/118) for the plain balloon catheter group, representing a difference of 24.63% (95% confidence interval, 14.68 to 34.58; P < 0.001). The secondary efficacy end point was primary target lesion patency at 12 months, which was 66% (74/112) for the DCB group and 46% (52/112) for the plain balloon catheter group (95% confidence interval, 6.57 to 32.08; P = 0.004). The mean number of reinterventions per patient to maintain target lesion patency during the 12 months after the index procedure was 0.39 (48/122) in the DCB group and 0.77 (94/122) in the plain balloon catheter group (P = 0.001). The primary safety end point did not differ between groups (P = 0.25). Conclusions: AcoArt Orchid DCB showed better primary patency rates compared with plain balloon angioplasty for treating stenotic lesions in dysfunctional hemodialysis AV fistulae at 6 and 12 months. It required fewer repeated interventions and had comparable safety in 1 year. Clinical Trial registry name and registration number: AcoArt III/Arterio-venous Fistula in China, NCT03366727.